WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME

WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME

The aim of the review is presenting the possibilities and perspectives of the third generation of thienopyridine P2Y12 receptor inhibitor prasugrel in the treatment of patients with acute coronary syndrome (ACS). The main pathogenetic stage of ACS is intracoronary thrombosis, which develops on the s...

Full description

Bibliographic Details
Main Authors:	M. Yu. Gilyarov, Е. V. Konstantinova
Format:	Article
Language:	English
Published:	Stolichnaya Izdatelskaya Kompaniya 2018-05-01
Series:	Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:	prasugrel dual antiplatelet therapy acute coronary syndromes myocardial infarction unstable angina coronary artery disease percutaneous coronary intervention clopidogrel prognosis safety of treatment
Online Access:	https://www.rpcardio.com/jour/article/view/1660

Similar Items

Prasugrel
by: Gianluca Airoldi, et al.
Published: (2013-04-01)

Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01)

Immediate and Long-Term Therapy of Patients with Acute Coronary Syndromes with Thienopyridines. Current Status According to the Latest European Society of Cardiology (ESC) Guidelines
by: Sigmund Silber
Published: (2011-07-01)

Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
by: T. M. Uskach, et al.
Published: (2020-12-01)

Ticagrelor
by: Gianluca Airoldi, et al.
Published: (2013-03-01)

The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention
by: A. S. Tereshchenko, et al.
Published: (2019-05-01)

Dual Antiplatelet Therapy in Coronary Artery Disease
by: Raghav Sharma, et al.
Published: (2020-08-01)

P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel
by: N. M. Vorobyeva
Published: (2019-01-01)

The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy
by: Stanislav Simek, et al.
Published: (2020-08-01)

Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk
by: O. V. Averkov
Published: (2021-02-01)

ANTIPLATELET THERAPY OF ACUTE CORONARY SYNDROME: CURRENT CAPAB ILITIES
by: E. V. Konstantinova, et al.
Published: (2018-07-01)

Vorapaxar
by: Gianluca Airoldi, et al.
Published: (2013-04-01)

Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis
by: Pravesh Kumar Bundhun, et al.
Published: (2018-05-01)

Nicorandil in patients with acute coronary syndrome and stable angina undergoing Percutaneous Coronary Intervention: literature review
by: Neda Partovi, et al.
Published: (2014-12-01)

Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis
by: Fan ZG, et al.
Published: (2019-02-01)

Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis
by: Xiaojun Zhuo, et al.
Published: (2018-09-01)

Clopidogrel in the treatment of patients with ST-elevation acute myocardial infarction: state-of-art in 2013
by: O. V. Averkov
Published: (2013-02-01)

COMPARISON OF EFFECTIVENESS OF PERCUTANEOUS CORONARY INTERVENTION AND MEDICATION IN PATIENTS WITH STABLE ANGINA
by: Afzal Qasim, et al.
Published: (2015-03-01)

Oral antiplatelet therapy and platelet inhibition: An experience from a tertiary care center
by: Jamshed J. Dalal, et al.
Published: (2016-09-01)

Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention
by: Kreutz RP, et al.
Published: (2016-06-01)

Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective
by: Gregorio Tersalvi, et al.
Published: (2020-07-01)

Coronary flow assessment in unstable angina/non st-segment elevation myocardial infarction patients via thrombolysis in myocardial infarction frame count in angiography
by: Hamidreza Sanati, et al.
Published: (2013-01-01)

Screening Characteristics of TIMI Score in Predicting Acute Coronary Syndrome Outcome; a Diagnostic Accuracy Study
by: Mostafa Alavi-Moghaddam, et al.
Published: (2016-12-01)

Screening Characteristics of TIMI Score in Predicting Acute Coronary Syndrome Outcome; a Diagnostic Accuracy Study
by: Mostafa Alavi-Moghaddam, et al.
Published: (2017-01-01)

Factors Associated With Initial Prasugrel Versus Clopidogrel Selection for Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From the Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE‐ACS) Study
by: Amit N. Vora, et al.
Published: (2016-09-01)

ASSOCIATION OF THROMBOLYSIS IN MYOCARDIAL INFARCTION (TIMI) RISK SCORE WITH EXTENT OF CORONARY ARTERY DISEASE IN PATIENTS WITH UNSTABLE ANGINA AND NSTEMI
by: Saleha Abbas, et al.
Published: (2020-12-01)

Percutaneous coronary intervention in a patient with single coronary artery
by: T.K. Mishra, et al.
Published: (2014-05-01)

Meta-analysis of Nicorandil effectiveness on myocardial protection after percutaneous coronary intervention
by: Xiao-Tao Zhao, et al.
Published: (2019-06-01)

What is new in 2015 ESC nonST Elevation Acute Coronary Syndrome Guideline?
by: Aylin Yıldırır
Published: (2016-02-01)

Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study
by: Ahmed Amro, et al.
Published: (2019-07-01)

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
by: Larisa H. Cavallari, et al.
Published: (2018-04-01)

Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
by: Yijiang Zhou, et al.
Published: (2017-06-01)

Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study
by: Hua Yan, et al.
Published: (2020-06-01)

CORONARY EMBOLISM WITH FRAGMENTED THROMBUS FROM THE LEFT VENTRICLE IN PATIENT WITH POSTINFARCTION ANEURYSM
by: Yu. F. Salakhova, et al.
Published: (2016-01-01)

Late opening of occluded coronary artery in myocardial infarction patients: is it always advisable?
by: S. V. Shalaev, et al.
Published: (2007-12-01)

Incidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention
by: S. Ramesh, et al.
Published: (2020-11-01)

A score for decision making during percutaneous coronary intervention in acute myocardial infarction patients with multivessel disease
by: Hae Chang Jeong, et al.
Published: (2019-03-01)

Consequences of escalation and de-escalation of double antiplatelet therapy in patients with acute coronary syndrome in real clinical practice
by: R. L. Shamraev, et al.
Published: (2019-04-01)

Comparison of serum parathyroid hormone level between patients with acute myocardial infarction, unstable angina, and normal coronary function
by: Alireza Rai, et al.
Published: (2019-12-01)

Double antiplatelet therapy in patients with acute coronary syndrome
by: A. V. Rodionov, et al.
Published: (2011-10-01)